Change in obesity-related metabolic abnormalities associated with body mass index improvement through life-style

Rhys Ib Matson1,2, Rachel Perry1, Linda P Hunt1

  • 1NIHR Bristol Biomedical Research Centre - Nutrition, University Hospitals Bristol Education Centre, Bristol, UK.

Pediatric Diabetes
|December 11, 2019
PubMed

Insights

Greater loss in body mass index standard deviation score (BMI-SDS) correlated with improved metabolic health markers in obese children. However, specific BMI-SDS reduction targets for metabolic improvement remain undetermined.

Area of Science:

  • Pediatric Endocrinology
  • Obesity Research
  • Metabolic Health

Background:

  • Obesity in children is linked to metabolic complications.
  • The precise reduction in Body Mass Index standard deviation score (BMI-SDS) needed to improve metabolic health markers is not well-established.
  • Clinical guidelines for pediatric weight management require evidence on the efficacy of BMI-SDS changes.

Purpose of the Study:

  • To determine the change in BMI-SDS associated with improvements in inflammation, liver function, and insulin resistance in obese children.
  • To inform clinical guidelines for pediatric weight management interventions.
  • To assess the efficacy of future clinical trials by establishing these associations.

Main Methods:

  • A systematic review and meta-regression analysis of 68 identified articles.
  • Inclusion criteria: studies on obese children undergoing lifestyle interventions, reporting BMI-SDS and metabolic markers (glucose, HOMA-IR, ALT, CRP, IL-6).
  • Meta-regressions analyzed the relationship between BMI-SDS change and changes in metabolic markers.

Main Results:

  • Greater mean reductions in HOMA-IR, Glucose, ALT, and CRP were observed with greater mean BMI-SDS loss.
  • Statistically significant trends were found for HOMA-IR (P = .003) and CRP (P = .021).
  • No minimum BMI-SDS reduction threshold was identified to guarantee improvements in these metabolic outcomes.

Conclusions:

  • While greater BMI-SDS reduction is associated with improved metabolic health markers like HOMA-IR and CRP, a specific target reduction is not yet defined.
  • Current evidence does not allow for the recommendation of a definitive BMI-SDS reduction value for metabolic health improvement in pediatric obesity.
  • Future research should consider reporting additional adiposity indices to better reflect changes during weight management interventions.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.8K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
202
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
136
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
173
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
285